SCHEMBL3673564

SCHEMBL3673564

N=C(N)c1ccc(O)c(S(N)(=O)=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.49
PRSS1 P07477 9/20 0.48
PRSS2 P07478 5/20 0.48
PRSS3 P35030 5/20 0.48
F12 P00748 1/20 0.44
LMNA P02545 1/20 0.43
F2 P00734 2/20 0.41
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41
KLKB1 P03952 1/20 0.41
KLK1 P06870 1/20 0.41
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
RAD52 P43351 1/20 0.40
UBE2N P61088 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA4 P22748 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7323111 0.87 F10 (0.48) F10PRSS1PRSS2PRSS3F12
SCHEMBL5527636 0.80 HDAC6 (0.38) F10PRSS1PRSS2PRSS3CA1
SCHEMBL10177955 0.78 PRSS1 (0.58) F10PRSS1PRSS2PRSS3F12
SCHEMBL9314470 0.74 LMNA (0.54) PRSS1PRSS2PRSS3F12LMNA
SCHEMBL10143513 0.74 PRSS1 (0.53) F10PRSS1PRSS2PRSS3F2
SCHEMBL12581534 0.74 PLAU (0.53) F10PRSS1PRSS2PRSS3F12
SCHEMBL7330212 0.73 PRSS1 (0.49) F10PRSS1PRSS2PRSS3PLAU
Hydrochloric Acid SCHEMBL4280302 0.73 LMNA (0.52) PRSS1PRSS2PRSS3F12LMNA
SCHEMBL27802082 0.73 PTGS1 (0.63) LMNAPOLBCA1CA2CA9
Hydrochloric Acid SCHEMBL9244161 0.72 F2 (0.51) F10PRSS1PRSS2PRSS3F12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009939-A1 CONCURRENT DRUGS KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-01-14 US claimed
US-7589126-B2 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US claimed
US-7563822-B2 Agents for the prevention or treatment of renal diseases KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-07-21 US claimed
EP-1331221-B1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION KISSEI PHARMACEUTICAL (JP) 2009-01-14 EP claimed
US-20070105825-A1 Concurrent drugs KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-05-10 US claimed
US-20070105829-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION Kissei Pharmaceutical Co.,Ltd. 2007-05-10 US claimed
US-7208524-B2 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-04-24 US claimed
EP-1679067-A1 CONCURRENT DRUGS Kissei Pharmaceutical Co., Ltd. (JP) 2006-07-12 EP claimed
US-20060116361-A1 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-06-01 US claimed
US-20050107354-A1 active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-05-19 US claimed
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US claimed
EP-1443041-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2004-08-04 EP claimed
EP-1331221-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION Kissei Pharmaceutical Co., Ltd. (JP) 2003-07-30 EP claimed
US-20100009939-A1 CONCURRENT DRUGS KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-01-14 US disclosed
US-20100009939-A1 CONCURRENT DRUGS KISSEI PHARMACEUTICAL CO., LTD. (JP) 2010-01-14 US disclosed
US-7589126-B2 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1331221-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION Kissei Pharmaceutical Co., Ltd. (JP) 2003-07-30 EP disclosed
WO-2003040086-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2003-05-15 WO disclosed
JP-2003104957-A BIPHENYLETHYLAMINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME KISSEI PHARMACEUT CO LTD 2003-04-09 JP disclosed
WO-2002028827-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION KISSEI PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107354-A1 active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative or a pharmaceutical acceptable salt thereof; excellent inhibitory effect on mesangial cell proliferation and decreasing effect on urine protein excretion REN, GLS, GRB2 F10 2371/4885PRSS1 396/4885PRSS2 77/4885
US-20100009939-A1 CONCURRENT DRUGS CYP3A5, HPSE, SLC9A5 F10 64/4885PRSS1 347/4885PRSS2 438/4885
US-20050014787-A1 5-amidino-2-hydroxybenzenesulfonamide derivatives medicinal compoistions containing the same medicinal use thereof and intermediates in the production thereof F2, HYPK, F10 F10 3/4885PRSS1 263/4885PRSS2 159/4885
US-20070105825-A1 Concurrent drugs CYP3A5, HPSE, SLC9A5 F10 64/4885PRSS1 347/4885PRSS2 438/4885
US-20060116361-A1 5-Amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation F12, F2, F5 F10 6/4885PRSS1 85/4885PRSS2 45/4885
US-20070105829-A1 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION F12, F2, F5 F10 6/4885PRSS1 85/4885PRSS2 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.